权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functional Genomics/Genomic Sequencing

功能基因组学/基因组测序

基本信息

批准号：
9179602
负责人：
MICHAEL A FRIEDMAN
金额：
$ 29.67万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-08-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9179602
关键词：
Antineoplastic Agents Area Atlas of Cancer Mortality in the United States Binding Biochemical Pathway Biological Biological Assay Biological Markers Cancer Biology Cancer Center Cancer Center Support Grant Cancer Gene Mutation Cell Proliferation Cell physiology Cells Classification Clinical Core Facility Coupled CpG Islands Custom DNA DNA Methylation DNA Microarray Chip DNA Sequencing Facility DNA biosynthesis DNA sequencing Dedications Development Developmental Process Diagnostic Disease Drug Targeting Early Diagnosis Elements Enzymes Epigenetic Process Eukaryota Evaluation Fingerprint Formalin Functional disorder Gene Chips Gene Expression Gene Expression Profile Gene Expression Profiling Gene Expression Regulation Gene Silencing Genes Genetic Recombination Genetic Transcription Genetic Variation Genome Genomics Genotype Goals Human Human Genome Individual Differences Instruction Investigation Investments Lead Link Malignant Neoplasms Maps Measurement Methylation Methyltransferase MicroRNAs Microfluidic Microchips Molecular Profiling Monitor Nucleotides Organism Paraffin Embedding Pathogenesis Pathologic Processes Pathway interactions Pattern Pharmaceutical Preparations Physiological Processes Proteins Publications Quantitative Reverse Transcriptase PCR RNA RNA Interference Research Research Personnel Resolution Resource Sharing Role Safety Sampling Screening for cancer Services Signal Pathway Single Nucleotide Polymorphism Site Small RNA System Systems Analysis Technology Toxic effect Training Transcript Treatment Efficacy United States National Institutes of Health Untranslated RNA Validation anticancer research base bead chip cancer biomarkers cancer diagnosis cancer genetics cancer genomics cancer risk cancer therapy carcinogenesis comparative genomic hybridization epigenomics experience fighting functional genomics genome sequencing genome-wide genome-wide analysis genomic biomarker genomic tools histone modification human disease improved innovation instrument instrumentation metaplastic cell transformation miRNA expression profiling molecular phenotype new therapeutic target next generation next generation sequencing novel novel marker novel therapeutics predicting response programs prospective rapid detection receptor targeted cancer therapy technology/technique therapeutic target tool transcriptome sequencing transcriptomics whole genome

项目摘要

PROJECT SUMMARY (See instructions); The overall goal of the Functional Genomics/Genomic Sequencing Core (FGC) is to provide state-of-the-art instruments, and expert scientific and technical advice in cancer genomics to COHCCC investigators. The FGC is equipped with major genomics instrumentation such as Affymetrix GeneChip� Analysis System, Agilent scanner/microarray system, Roche NimbleGen MS200 microarray scanner/system, lllumina HiScanSQ, HiSeq2000, GA llx and Roche 454 FLX. The core also has a next-generation ABI Taqman Realtime PCR system ViiA 7 for microarray validation. FGC provides comprehensive genomic support including transcriptomic and mlRNA/smRNA profiling by,microarrays and RNA-Seq/smRNA-Seq, ChlP-Chip/ChlPSeq, DNA methylation, DNA-Seq including whole genome and target genome sequencing, microarray genome-wide and custom genotyping, SNP/CNV, aCGH, RNAi and qRT-PCR. The FGC has recently set up numerous new genomic technologies and assays including microarray-coupled genome-wide gene expression profiling using difficult clinical formalin-fixed paraffin-embedded (FFPE) RNA samples, smRNASeq and RNA-Seq using FFPE-derived samples, microfluidic chip- and microarray-coupled single-cell genome-wide gene expression profiling. In addition, the FGC has implemented NimbleGen array-based comprehensive high-throughput arrays for relative methylation (CHARM), Affymetrix DMET and genomewide human SNP 6.0 array genotyping, and lllumina Infinium HumanMethylation450 BeadChip that interrogates more than 450,000 methylation sites across the whole human genome at single-nucleotide resolution. The FGC has supported numerous NIH/NCI projects resulting in high impact publications. In summary, the advanced genomic tools in the FGC allow COHCCC investigators to: 1) identify cancer gene mutations at high-throughput rates; 2) map cancer genomic, transcriptomic and epigenomic fingerprints to identify genomic biomarkers for cancer early detection and diagnosis; 3) identify novel therapeutic targets against cancers; and 4) predict responses to therapy.

项目总结（见说明）; 功能基因组学/基因组测序核心（FGC）的总体目标是为COHCCC研究人员提供癌症基因组学方面的最先进仪器以及专家科学和技术建议。FGC配备了主要的基因组学仪器，如Affychip GeneChip分析系统，Agilent扫描仪/微阵列系统，Roche NimbleGen MS 200微阵列扫描仪/系统，Illumina HiScanSQ，HiSeq 2000，GA llx和Roche 454 FLX。该核心还具有用于微阵列验证的下一代ABI Taqman Realtime PCR系统ViiA 7。FGC提供全面的基因组支持，包括微阵列和RNA-Seq/smRNA-Seq、ChIP-Chip/ChIPSeq、DNA甲基化、DNA-Seq（包括全基因组和靶基因组测序）、微阵列全基因组和定制基因分型、SNP/CNV、aCGH、RNAi和qRT-PCR的转录组学和mRNA/smRNA分析。FGC最近建立了许多新的基因组技术和测定，包括使用困难的临床福尔马林固定石蜡包埋（FFPE）RNA样品的微阵列偶联的全基因组基因表达谱，使用FFPE衍生样品的smRNASeq和RNA-Seq，微流体芯片和微阵列偶联的单细胞全基因组基因表达谱。此外，FGC还实施了基于NimbleGen阵列的综合高通量相对甲基化阵列（CHARM）、Affymetrix DMET和全基因组人类SNP 6.0阵列基因分型，以及Illumina Infinium HumanMethylation 450 BeadChip，以单核苷酸分辨率询问整个人类基因组中超过450，000个甲基化位点。FGC支持了许多NIH/NCI项目，产生了高影响力的出版物。总之，FGC中先进的基因组工具允许COHCCC研究人员：1）以高通量率鉴定癌症基因突变; 2）绘制癌症基因组、转录组和表观基因组指纹图谱，以鉴定用于癌症早期检测和诊断的基因组生物标志物; 3）鉴定针对癌症的新治疗靶点; 4）预测对治疗的反应。